Back to today’s briefing

Story perspectives

AstraZeneca Posts $2.5 B Q2 Profit, Reaffirms 2030 Target

7/27/2026

50 9 Full Breakdown

Summary

Story summary

AstraZeneca reported second-quarter net profit of $2.5 billion, up more than two percent year over year.
Revenue rose 5% to $15.38 billion, driven by 15% oncology growth and 8% rare-disease growth.
CEO Pascal Soriot reaffirmed full-year guidance and the $80 billion 2030 revenue target despite the recent failure of the heart-disease drug Wainua.
Shares rose about 1.7% by 0925 GMT, though they remain roughly 7% lower for the year.

1 of 1

Story summary

AstraZeneca reported second-quarter net profit of $2.5 billion, up more than two percent year over year.
Revenue rose 5% to $15.38 billion, driven by 15% oncology growth and 8% rare-disease growth.
CEO Pascal Soriot reaffirmed full-year guidance and the $80 billion 2030 revenue target despite the recent failure of the heart-disease drug Wainua.
Shares rose about 1.7% by 0925 GMT, though they remain roughly 7% lower for the year.